View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsNanomix 将来の成長Future 基準チェック /06現在、 Nanomixの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Medical Equipment 収益成長16.1%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Apr 10Nanomix Corporation Common Stock Deleted from OTC EquityNanomix Corporation Common Stock has been deleted from OTC Equity effective April 09, 2025, due to 12(j)Registration Revoked by SEC.お知らせ • Nov 27Nanomix Corporation Announces Chief Executive Officer ChangesOn November 3, 2023 (the “Effective Date”), Nanomix Corporation appointed David Ludvigson as interim chief executive officer of the Company, effective immediately. Mr. Ludvigson succeeds Dr. Thomas Schlumpberger who unexpectedly passed away on November 2, 2023. Mr. Ludvigson served as chief executive officer of the Company from June 2021 to July 2022, chief financial officer from June 2021 until January 2023 and as a director since June 2021. From June 2013 to June 2021, he served as CEO of Nanomix Inc. From October 2009 through present day, Mr. Ludvigson has served as President of Knight Ludvigson Advisors providing advisory and business consulting services to Life Science and Technology companies including M&A, financing, business strategy, go to market planning and sales channel strategy and implementation. Mr. Ludvigson serves on the board of directors of Imagion Biosystems Inc., One BioMed PTE LTD (privately held), Incando Therapeutics Inc. (privately held) and China Stem Cells Ltd. (privately held). Mr. Ludvigson received his BS and MAS in Accounting from Gies College of Business – University of Illinois Urbana-Champaign.お知らせ • May 16Nanomix Corporation announced delayed 10-Q filingOn 05/15/2023, Nanomix Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jan 26Nanomix Corporation Appoints Christopher R. Hetterly as Chief Financial OfficerNanomix Corporation announced the appointment of Christopher R. Hetterly as Chief Financial Officer (CFO). Mr. Hetterly is a financial executive and entrepreneur, with over 25 years of financial leadership and banking experience. Previously, Mr. Hetterly was the CFO of Octagos Health, a healthcare Software-as-a-Service (SaaS) company. Prior to that, he was a CFO at Madrona Ventures portfolio companies. Mr. Hetterly was the Head of Technology Finance at GE Capital, Wells Fargo, and East West Bank, in addition to being CFO/CIO at Palo Alto Capital. He has raised capital from seed stage to IPO and beyond, and has experience in debt and equity financing, corporate development, business development, with particular expertise in building finance teams and leading in high growth environments. Mr. Hetterly has raised over $10 billion in capital in his career for well-known names such as eBay, Netflix and Symantec amongst others, and his financing experience includes venture capital, corporate, mezzanine, lease, bank credit line, LBO, IPO and secondary public sources. He graduated from Brown University with a BA from the Honors Program.お知らせ • Sep 01+ 1 more updateNanomix Names Tadd S. Lazarus to Board of DirectorsNanomix Names Tadd S. Lazarus to Board of Directors.お知らせ • Jul 27+ 1 more updateNanomix Corporation Appoints Thomas Schlumpberger as Member of the Board of DirectorsNanomix Corporation announced the appointment of Dr. Thomas Schlumpberger as member of the Board of Directors, effective immediately. Dr. Schlumpberger is a recognized expert in POC diagnostics and a seasoned senior executive with more than 20 years in the life sciences industry. His broad base of experience is directly applicable to the next phase of growth at Nanomix as the Company’s POC platform gains customer adoption. At Epocal, a POC company, he was responsible for international business and business development. He successfully launched a point-of-care product in India, Japan and Europe and, notably, he led the sale of Epocal to Alere. At Singulex, he concluded an investment from Grifols and successfully launched an ultra-high sensitivity assay in Europe. Most recently, as CEO of Pictor Limited, he successfully revamped the product portfolio and launched a COVID-19 antibody product successfully into several CLIA-certified laboratories. Dr. Schlumpberger has held senior executive roles with several other diagnostic companies, including Anixa, InVitae, Inivata, and Affymetrix. He received his Ph.D. in molecular and cell biology with distinction from the University of California, Berkeley.お知らせ • Jun 23Nanomix Corporation Initiates New Clinical Study for the eLab S1 PanelNanomix Corporation announced that it has initiated a clinical validation study with Hospital Clinico San Carlos (HCSC) in Madrid, Spain to evaluate the performance of the Nanomix eLab® mobile immunoassay diagnostic system and the S1 Panel assay for the detection of critical infections such as sepsis in the emergency department. The principal investigator of the study is Dr. Juan González del Castillo, Internal Medicine Specialist, Assistant Physician of the Emergency Service of HCSC and Coordinator of the Infections Group of the Spanish Society of Emergency Medicine (SEMES). The Nanomix eLab® system is a mobile, hand-held immunoassay and chemistry diagnostic system designed for the needs of rapid point-of-care testing. The Nanomix eLab® system offers a variety of benefits, including results in minutes, lower cost, and portability, while providing accurate, quantitative results comparable in quality to those provided by central lab testing. Furthermore, the S1 Panel Cartridge was developed as an aid in rapidly diagnosing critical infections including sepsis. The panel provides quantitative test results for procalcitonin (PCT), C-reactive protein (CRP) and lactate (LAC) from a single venous whole blood or plasma sample type. The assay runs on the eLab Analyzer with results available in approximately 12 minutes from sample to answer, versus the current diagnostic solutions which can take hours to provide a test result. The S1 Panel assay has received the CE marking in Europe and has UK Medicines and Healthcare products Regulatory Agency (MHRA) registration.お知らせ • Jun 15Nanomix Corporation Receives IVDR Certification for the eLab AnalyzerNanomix Corporation announced that it has received the EU Quality Management System Certificate under the new In Vitro Diagnostic Medical Devices Regulation (IVDR) for its eLab analyzer, part of the Nanomix eLab® system. The European Union (EU) IVDR replaces the legacy In Vitro Diagnostic Directive (IVDD) and was created to ensure a greater level of patient protection and regulation around the creation of in vitro diagnostic devices (IVDs). The Nanomix eLab® system is a rapid, easy-to-use, quantitative detection platform that performs a range of in vitro diagnostic assays. The platform consists of a hand-held analyzer and a disposable cartridge. The eLab System utilizes a proprietary nano-biosensor with multiple detection electrodes to generate multiple electrochemical assay results from a single patient sample. The Nanomix eLab® system offers a variety of benefits, including results in minutes, lower cost, and portability, while providing accurate, quantitative results comparable in quality to those provided by central lab testing. The Nanomix eLab® system has received the CE marking in Europe.お知らせ • May 27Nanomix Granted Ce Mark for Elab S1 Assay Panel for Whole Blood SamplesNanomix Corporation announced that it has received European CE mark designation for its eLab S1 assay panel for use with a lithium heparinized whole blood sample. The eLab S1 is currently marketed and CE marked for use with a plasma sample. The new authorization for a whole blood sample provides even faster results than the Company's earlier plasma-based panel by eliminating the step of first centrifuging blood to produce a plasma sample. Key Advantages: The ab b S1 assay panel is the first of its kind offering Procalcitonin(PCT), C-Reactive Protn (CRP) and LaLactate (LAC) for use on its testing device in emergency departments and decentralized healthcare environments,Faster time to results -- driving information within the initial clinical decision-making window,Increased accessibility and broader end-user market,Designed to help providers achieve better patient outcomes . The S1 Assay panel was developed as an aid in rapidly diagnosing critical infections including sepsis. The panel provides quantitative test results for LAC, CRP and PCT from a single plasma sample or venous whole blood sample type. The assay runs on the eLab Analyzer with results available in approximately 12 minutes from sample to answer, versus the current diagnostic solutions which can take hours to provide a test result. The Nanomix eLab(R) system is a mobile, hand-held immunoassay and chemistry diagnostic system designed for the needs of rapid point-of-care testing. The Nanomix eLab(R) offers a variety of benefits, including results in minutes, lower cost, and portability, while providing accurate, quantitative results comparable in quality to those provided by central lab testing. About Nanomix CorporationNanomix (OTCQB: NNMX) is developing mobile point-of-care diagnostics with its Nan mix eLab(R) System platform and assays that provide rapid, accurate, quantitative information for use in settings where time is critical to clinical decision-making and improved patient care. The company's products are designed to broadly impact healthcare delivery by bringing diagnostics to the point of initial patient interaction, whether in the hospital or in pre-hospital, remote or alternate-care settings, thereby enabling faster clinical decision-making and potentially treatment-in-place. Nanomix's first assays address the need for faster diagnosis of critical infections as well as the rapid identification of current and prior SARS-CoV-2 infection. The company is developing a pipeline of other tests designed to improve patient outcomes by making high-quality diagnostic information available within minutes.お知らせ • May 18Nanomix Corporation announced delayed 10-Q filingOn 05/17/2022, Nanomix Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Mar 31Nanomix Corporation Appoints Vidur Sahney as Chief Operating OfficerNanomix Corporation announced the appointment of Vidur Sahney as Chief Operating Officer. Mr. Sahney brings to Nanomix more than 20 years of experience in operations, quality, validation, manufacturing and research. In this newly created executive management position, Mr. Sahney will manage and be responsible for Nanomix operations including manufacturing, assay development and quality. Most recently, Mr. Sahney served as Chief Operating Officer of ExThera Medical where he led the initiative to secure U.S. Food and Drug Administration (FDA) Emergency Use Authorization site clearance and CE mark for a Class III /PMA medical device, and commercialized the novel hemoperfusion filter used to treat blood stream infections and COVID-19 in Europe and the U.S.お知らせ • Mar 30Nanomix Corporation announced delayed annual 10-K filingOn 03/29/2022, Nanomix Corporation announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Dec 09Nanomix Announces UK MHRA Registration for New Point of Care SystemNanomix Corporation announced confirmation of registration from the Medicines & Healthcare products Regulatory Agency (MHRA) of the United Kingdom for the Nanomix eLab system and the S1 Panel Cartridge. The Nanomix eLab analyzer with S1 Panel Cartridge provides multiple host-response biomarker results that can assist healthcare providers in diagnosing and treating patients with critical infections, including sepsis.お知らせ • Dec 02Nanomix Corporation Submits Emergency Use Authorization Application for its Rapid Point-of-Care Antigen Panel to Detect COVID-19Nanomix Corporation announced the Company has resubmitted an Emergency Use Authorization (EUA) application to the U.S. Food and Drug Administration (FDA) for its eLab COVID-19 rapid antigen test. The application includes additional analytical and clinical development documentation in response to FDA review comments. The COVID-19 Antigen test cartridge is used with the Nanomix eLab Analyzer to provide electronically available results in 15 minutes. The Nanomix COVID-19 Rapid Antigen Test provides qualitative detection of nucleocapsid antigen from SARS-CoV-2 in nasal (anterior nares) swabs. Nasal swab samples are collected using a provided swab and sample collection tube and then transferred to the single-use, microfluidic cartridge. The cartridge is run on the Nanomix eLab Analyzer which displays results in 15 minutes with the ability to print or send results electronically via Bluetooth. Additionally, the eLab system can publish Nanomix eLab COVID-19 Rapid Antigen Test results output as a QR code for privacy.お知らせ • Aug 17Boston Therapeutics, Inc. announced delayed 10-Q filingOn 08/16/2021, Boston Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Nanomix は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:NNMX - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20220-13-6-6N/A9/30/20220-12-6-6N/A6/30/20220-10-8-8N/A3/31/2022N/A-11-7-7N/A12/31/20210-9-7-6N/A9/30/20210-9-5-5N/A6/30/20210-8-3-3N/A3/31/20210-6-3-3N/A12/31/20201-6-4-4N/A12/31/20190-6-5-5N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: NNMXの予測収益成長が 貯蓄率 ( 2.8% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: NNMXの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: NNMXの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: NNMXの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: NNMXの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: NNMXの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/04/09 10:09終値2025/02/24 00:00収益2022/12/31年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Nanomix Corporation 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Apr 10Nanomix Corporation Common Stock Deleted from OTC EquityNanomix Corporation Common Stock has been deleted from OTC Equity effective April 09, 2025, due to 12(j)Registration Revoked by SEC.
お知らせ • Nov 27Nanomix Corporation Announces Chief Executive Officer ChangesOn November 3, 2023 (the “Effective Date”), Nanomix Corporation appointed David Ludvigson as interim chief executive officer of the Company, effective immediately. Mr. Ludvigson succeeds Dr. Thomas Schlumpberger who unexpectedly passed away on November 2, 2023. Mr. Ludvigson served as chief executive officer of the Company from June 2021 to July 2022, chief financial officer from June 2021 until January 2023 and as a director since June 2021. From June 2013 to June 2021, he served as CEO of Nanomix Inc. From October 2009 through present day, Mr. Ludvigson has served as President of Knight Ludvigson Advisors providing advisory and business consulting services to Life Science and Technology companies including M&A, financing, business strategy, go to market planning and sales channel strategy and implementation. Mr. Ludvigson serves on the board of directors of Imagion Biosystems Inc., One BioMed PTE LTD (privately held), Incando Therapeutics Inc. (privately held) and China Stem Cells Ltd. (privately held). Mr. Ludvigson received his BS and MAS in Accounting from Gies College of Business – University of Illinois Urbana-Champaign.
お知らせ • May 16Nanomix Corporation announced delayed 10-Q filingOn 05/15/2023, Nanomix Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jan 26Nanomix Corporation Appoints Christopher R. Hetterly as Chief Financial OfficerNanomix Corporation announced the appointment of Christopher R. Hetterly as Chief Financial Officer (CFO). Mr. Hetterly is a financial executive and entrepreneur, with over 25 years of financial leadership and banking experience. Previously, Mr. Hetterly was the CFO of Octagos Health, a healthcare Software-as-a-Service (SaaS) company. Prior to that, he was a CFO at Madrona Ventures portfolio companies. Mr. Hetterly was the Head of Technology Finance at GE Capital, Wells Fargo, and East West Bank, in addition to being CFO/CIO at Palo Alto Capital. He has raised capital from seed stage to IPO and beyond, and has experience in debt and equity financing, corporate development, business development, with particular expertise in building finance teams and leading in high growth environments. Mr. Hetterly has raised over $10 billion in capital in his career for well-known names such as eBay, Netflix and Symantec amongst others, and his financing experience includes venture capital, corporate, mezzanine, lease, bank credit line, LBO, IPO and secondary public sources. He graduated from Brown University with a BA from the Honors Program.
お知らせ • Sep 01+ 1 more updateNanomix Names Tadd S. Lazarus to Board of DirectorsNanomix Names Tadd S. Lazarus to Board of Directors.
お知らせ • Jul 27+ 1 more updateNanomix Corporation Appoints Thomas Schlumpberger as Member of the Board of DirectorsNanomix Corporation announced the appointment of Dr. Thomas Schlumpberger as member of the Board of Directors, effective immediately. Dr. Schlumpberger is a recognized expert in POC diagnostics and a seasoned senior executive with more than 20 years in the life sciences industry. His broad base of experience is directly applicable to the next phase of growth at Nanomix as the Company’s POC platform gains customer adoption. At Epocal, a POC company, he was responsible for international business and business development. He successfully launched a point-of-care product in India, Japan and Europe and, notably, he led the sale of Epocal to Alere. At Singulex, he concluded an investment from Grifols and successfully launched an ultra-high sensitivity assay in Europe. Most recently, as CEO of Pictor Limited, he successfully revamped the product portfolio and launched a COVID-19 antibody product successfully into several CLIA-certified laboratories. Dr. Schlumpberger has held senior executive roles with several other diagnostic companies, including Anixa, InVitae, Inivata, and Affymetrix. He received his Ph.D. in molecular and cell biology with distinction from the University of California, Berkeley.
お知らせ • Jun 23Nanomix Corporation Initiates New Clinical Study for the eLab S1 PanelNanomix Corporation announced that it has initiated a clinical validation study with Hospital Clinico San Carlos (HCSC) in Madrid, Spain to evaluate the performance of the Nanomix eLab® mobile immunoassay diagnostic system and the S1 Panel assay for the detection of critical infections such as sepsis in the emergency department. The principal investigator of the study is Dr. Juan González del Castillo, Internal Medicine Specialist, Assistant Physician of the Emergency Service of HCSC and Coordinator of the Infections Group of the Spanish Society of Emergency Medicine (SEMES). The Nanomix eLab® system is a mobile, hand-held immunoassay and chemistry diagnostic system designed for the needs of rapid point-of-care testing. The Nanomix eLab® system offers a variety of benefits, including results in minutes, lower cost, and portability, while providing accurate, quantitative results comparable in quality to those provided by central lab testing. Furthermore, the S1 Panel Cartridge was developed as an aid in rapidly diagnosing critical infections including sepsis. The panel provides quantitative test results for procalcitonin (PCT), C-reactive protein (CRP) and lactate (LAC) from a single venous whole blood or plasma sample type. The assay runs on the eLab Analyzer with results available in approximately 12 minutes from sample to answer, versus the current diagnostic solutions which can take hours to provide a test result. The S1 Panel assay has received the CE marking in Europe and has UK Medicines and Healthcare products Regulatory Agency (MHRA) registration.
お知らせ • Jun 15Nanomix Corporation Receives IVDR Certification for the eLab AnalyzerNanomix Corporation announced that it has received the EU Quality Management System Certificate under the new In Vitro Diagnostic Medical Devices Regulation (IVDR) for its eLab analyzer, part of the Nanomix eLab® system. The European Union (EU) IVDR replaces the legacy In Vitro Diagnostic Directive (IVDD) and was created to ensure a greater level of patient protection and regulation around the creation of in vitro diagnostic devices (IVDs). The Nanomix eLab® system is a rapid, easy-to-use, quantitative detection platform that performs a range of in vitro diagnostic assays. The platform consists of a hand-held analyzer and a disposable cartridge. The eLab System utilizes a proprietary nano-biosensor with multiple detection electrodes to generate multiple electrochemical assay results from a single patient sample. The Nanomix eLab® system offers a variety of benefits, including results in minutes, lower cost, and portability, while providing accurate, quantitative results comparable in quality to those provided by central lab testing. The Nanomix eLab® system has received the CE marking in Europe.
お知らせ • May 27Nanomix Granted Ce Mark for Elab S1 Assay Panel for Whole Blood SamplesNanomix Corporation announced that it has received European CE mark designation for its eLab S1 assay panel for use with a lithium heparinized whole blood sample. The eLab S1 is currently marketed and CE marked for use with a plasma sample. The new authorization for a whole blood sample provides even faster results than the Company's earlier plasma-based panel by eliminating the step of first centrifuging blood to produce a plasma sample. Key Advantages: The ab b S1 assay panel is the first of its kind offering Procalcitonin(PCT), C-Reactive Protn (CRP) and LaLactate (LAC) for use on its testing device in emergency departments and decentralized healthcare environments,Faster time to results -- driving information within the initial clinical decision-making window,Increased accessibility and broader end-user market,Designed to help providers achieve better patient outcomes . The S1 Assay panel was developed as an aid in rapidly diagnosing critical infections including sepsis. The panel provides quantitative test results for LAC, CRP and PCT from a single plasma sample or venous whole blood sample type. The assay runs on the eLab Analyzer with results available in approximately 12 minutes from sample to answer, versus the current diagnostic solutions which can take hours to provide a test result. The Nanomix eLab(R) system is a mobile, hand-held immunoassay and chemistry diagnostic system designed for the needs of rapid point-of-care testing. The Nanomix eLab(R) offers a variety of benefits, including results in minutes, lower cost, and portability, while providing accurate, quantitative results comparable in quality to those provided by central lab testing. About Nanomix CorporationNanomix (OTCQB: NNMX) is developing mobile point-of-care diagnostics with its Nan mix eLab(R) System platform and assays that provide rapid, accurate, quantitative information for use in settings where time is critical to clinical decision-making and improved patient care. The company's products are designed to broadly impact healthcare delivery by bringing diagnostics to the point of initial patient interaction, whether in the hospital or in pre-hospital, remote or alternate-care settings, thereby enabling faster clinical decision-making and potentially treatment-in-place. Nanomix's first assays address the need for faster diagnosis of critical infections as well as the rapid identification of current and prior SARS-CoV-2 infection. The company is developing a pipeline of other tests designed to improve patient outcomes by making high-quality diagnostic information available within minutes.
お知らせ • May 18Nanomix Corporation announced delayed 10-Q filingOn 05/17/2022, Nanomix Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Mar 31Nanomix Corporation Appoints Vidur Sahney as Chief Operating OfficerNanomix Corporation announced the appointment of Vidur Sahney as Chief Operating Officer. Mr. Sahney brings to Nanomix more than 20 years of experience in operations, quality, validation, manufacturing and research. In this newly created executive management position, Mr. Sahney will manage and be responsible for Nanomix operations including manufacturing, assay development and quality. Most recently, Mr. Sahney served as Chief Operating Officer of ExThera Medical where he led the initiative to secure U.S. Food and Drug Administration (FDA) Emergency Use Authorization site clearance and CE mark for a Class III /PMA medical device, and commercialized the novel hemoperfusion filter used to treat blood stream infections and COVID-19 in Europe and the U.S.
お知らせ • Mar 30Nanomix Corporation announced delayed annual 10-K filingOn 03/29/2022, Nanomix Corporation announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Dec 09Nanomix Announces UK MHRA Registration for New Point of Care SystemNanomix Corporation announced confirmation of registration from the Medicines & Healthcare products Regulatory Agency (MHRA) of the United Kingdom for the Nanomix eLab system and the S1 Panel Cartridge. The Nanomix eLab analyzer with S1 Panel Cartridge provides multiple host-response biomarker results that can assist healthcare providers in diagnosing and treating patients with critical infections, including sepsis.
お知らせ • Dec 02Nanomix Corporation Submits Emergency Use Authorization Application for its Rapid Point-of-Care Antigen Panel to Detect COVID-19Nanomix Corporation announced the Company has resubmitted an Emergency Use Authorization (EUA) application to the U.S. Food and Drug Administration (FDA) for its eLab COVID-19 rapid antigen test. The application includes additional analytical and clinical development documentation in response to FDA review comments. The COVID-19 Antigen test cartridge is used with the Nanomix eLab Analyzer to provide electronically available results in 15 minutes. The Nanomix COVID-19 Rapid Antigen Test provides qualitative detection of nucleocapsid antigen from SARS-CoV-2 in nasal (anterior nares) swabs. Nasal swab samples are collected using a provided swab and sample collection tube and then transferred to the single-use, microfluidic cartridge. The cartridge is run on the Nanomix eLab Analyzer which displays results in 15 minutes with the ability to print or send results electronically via Bluetooth. Additionally, the eLab system can publish Nanomix eLab COVID-19 Rapid Antigen Test results output as a QR code for privacy.
お知らせ • Aug 17Boston Therapeutics, Inc. announced delayed 10-Q filingOn 08/16/2021, Boston Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.